DK0749752T3 - Anvendelse af specifikke RXR-receptor-ligander - Google Patents

Anvendelse af specifikke RXR-receptor-ligander

Info

Publication number
DK0749752T3
DK0749752T3 DK96401140T DK96401140T DK0749752T3 DK 0749752 T3 DK0749752 T3 DK 0749752T3 DK 96401140 T DK96401140 T DK 96401140T DK 96401140 T DK96401140 T DK 96401140T DK 0749752 T3 DK0749752 T3 DK 0749752T3
Authority
DK
Denmark
Prior art keywords
specific
ligand
receptor ligands
rxr receptor
specific rxr
Prior art date
Application number
DK96401140T
Other languages
Danish (da)
English (en)
Inventor
Andre Jomard
Michel Demarchez
Original Assignee
Galderma Rech Dermatologique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Rech Dermatologique filed Critical Galderma Rech Dermatologique
Application granted granted Critical
Publication of DK0749752T3 publication Critical patent/DK0749752T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK96401140T 1995-06-19 1996-05-28 Anvendelse af specifikke RXR-receptor-ligander DK0749752T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9507300A FR2735367B1 (fr) 1995-06-19 1995-06-19 Utilisation de ligands specifiques des recepteurs rxrs

Publications (1)

Publication Number Publication Date
DK0749752T3 true DK0749752T3 (da) 2002-08-26

Family

ID=9480139

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96401140T DK0749752T3 (da) 1995-06-19 1996-05-28 Anvendelse af specifikke RXR-receptor-ligander

Country Status (11)

Country Link
US (1) US6004987A (de)
EP (1) EP0749752B1 (de)
JP (1) JP2804014B2 (de)
AT (1) ATE217193T1 (de)
AU (1) AU688216B2 (de)
CA (1) CA2179426A1 (de)
DE (1) DE69621076T2 (de)
DK (1) DK0749752T3 (de)
ES (1) ES2179168T3 (de)
FR (1) FR2735367B1 (de)
PT (1) PT749752E (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753091B1 (fr) * 1996-09-09 2001-03-16 Oreal Utilisation d'un agoniste des recepteurs des retinoides de type rxr pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
HUP0001938A3 (en) * 1997-01-24 2001-09-28 Univ California Use of fxr, pparalpha and lxralpha activators for producing pharmaceutical compositions useful for restoring barrier function, promoting epidermal differentiation and inhibiting proliferation
EP0973390A4 (de) * 1997-04-11 2003-03-19 Sidney Kimmel Cancer Ct Mit retinoiden verwandte verbindungen zur hemmung krankhafter endothelin-1-überproduktion
FR2767058B1 (fr) * 1997-08-05 2000-05-05 Centre Nat Rech Scient Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
EP0908179A1 (de) * 1997-08-23 1999-04-14 Werner Bollag Behandlung von zellvermittelten Immunkrankheiten
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US20030113281A1 (en) * 1998-05-06 2003-06-19 Galderma Research & Development, S.N.C. Assay for identification of compounds that promote melanin production and retinoid-like compounds identified by said assay
CN1247192C (zh) * 1998-05-06 2006-03-29 盖尔德马研究及发展公司 鉴别促进黑色素生成的化合物的检定法及有关化合物
CA2374260A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
MXPA01012495A (es) * 1999-06-01 2003-09-10 Univ Texas Southwestern Med Ct Metodo para tratar la perdida capilar con el uso de derivados de difenilmetano.
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
JP2003500432A (ja) * 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター ジフェニルエーテル誘導体を用いて脱毛症を処置する方法
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
US20060079490A1 (en) * 2001-01-25 2006-04-13 Deluca Hector F Method of treatment of type I diabetes
US20030018017A1 (en) * 2001-01-25 2003-01-23 Deluca Hector F. Method of treatment of type I diabetes
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
CN101316584A (zh) * 2005-09-27 2008-12-03 北海道公立大学法人札幌医科大学 用于预防及治疗由血管通透性亢进引起的眼病的医药

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69324043T2 (de) * 1993-01-11 1999-07-01 Ligand Pharm Inc Verbindungen mit selektiver wirkung fuer retinoid x rezeptoren, und mittel fuer steuerung fuer durch retinoid x rezeptoren bedingte prozesse
WO1994015901A1 (en) * 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations

Also Published As

Publication number Publication date
JPH092972A (ja) 1997-01-07
DE69621076D1 (de) 2002-06-13
FR2735367B1 (fr) 1997-07-18
CA2179426A1 (fr) 1996-12-20
PT749752E (pt) 2002-08-30
DE69621076T2 (de) 2002-08-29
ES2179168T3 (es) 2003-01-16
JP2804014B2 (ja) 1998-09-24
EP0749752B1 (de) 2002-05-08
FR2735367A1 (fr) 1996-12-20
EP0749752A1 (de) 1996-12-27
ATE217193T1 (de) 2002-05-15
AU688216B2 (en) 1998-03-05
AU5470396A (en) 1997-01-16
US6004987A (en) 1999-12-21

Similar Documents

Publication Publication Date Title
DK0749752T3 (da) Anvendelse af specifikke RXR-receptor-ligander
DK0831769T3 (da) Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser
ATE286035T1 (de) Nichtsteroidale (hetero)zyklisch-substituierte acylanilide mit gemischter gestagener und androgener wirksamkeit
ATE241350T1 (de) Transdermale verabreichungsform von flurbiprofen
DE59509013D1 (de) Fahrstabilitätsregler mit reibwertabhängiger begrenzung der referenzgierrate
AU2671077A (en) Substrate coated with receptor and labelled ligand for assays
DE59208587D1 (de) Mischer mit Vorsatz
DK286589D0 (da) Apparat til fremstilling af bituminoese belagte produkter med en stationaer blandeindretning
DK239886D0 (da) Arrangement til bestemmelse af graden af konsistens hos en egenskabfor et omraade i et i diskrete billedelementer opdelt billede
NO933860D0 (no) Ekstracellulaere matriks-reseptorligander som modulerer leukocyttfunksjon
NO870923D0 (no) Apparat for styring av lasthaandteringsposisjon.
DE3686922T2 (de) Ablenkungsschaltung mit modulatorschaltung mit schaltmodus.
DE69500085D1 (de) Synergistische Mischung mindestens eines RXR-spezifischen Liganden mit mindestenseinem RAR-Alpha spezifischen Liganden
AU2240701A (en) Method and device relating to coating a running web
DE69318498T2 (de) Entwickler vom Ascorbinsäure-Typ und mit einer bestimmten Zusammensetzung
DE69530049D1 (de) Anzeigetafel mit polymerdispergiertem Flüssigkristall
DK466687A (da) Apparat til paaviikling af en foliebane paa en viklekerne
DE69610384T2 (de) Fotopolymerisierbare Zusammensetzung und fotographische Druckplatte unter Verwendung derselben
DE69000986D1 (de) Verbindung von reibmaterial mit beschichtetem grundkoerper.
DE69524918D1 (de) Flüssigkristall, Flüssigkristallmischung und Flüssigkristallvorrichtung, die diese enthält
AU584670B2 (en) Plate web girder
SU662157A1 (ru) Устройство дл нанесени порошкообразных материалов
ES255567U (es) Dispositivo perfeccionado para fijacion de plafones
AU8064582A (en) Concrete metering, distributing and levelling device
FR2738100B1 (fr) Dispositif de modulation de puissance d'une charge resistive